RayKnowChina Research Map
Shortlist0

RecruitingMultiple myelomaPhase 1/Phase 2

Registered title, quoted from ClinicalTrials.gov

To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma

An open trial on multiple myeloma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 4 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 4

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteFirst Affiliated Hospital of Soochow University苏州大学附属第一医院SuzhouHospital page
  2. Study siteHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page
  3. Study siteSecond Affiliated Hospital of Xi'an Jiaotong University西安交通大学第二附属医院Xi'anHospital page
  4. Study siteSecond Affiliated Hospital, Zhejiang University浙江大学医学院附属第二医院HangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07454187, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to 80 years; sex: all

    Registered eligibility fields

  2. Resolution of adverse events related to prior antineoplastic therapy to Grade ≤ 1 or baseline (CTCAE v6.0).

    Inclusion criterion 7

  3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2.

    Inclusion criterion 2

  4. Any other malignancy diagnosed within 5 years prior to the first dose.

    Exclusion criterion 25

  5. Female participants of childbearing potential and male participants whose partners are of childbearing potential must use at least one acceptable method of contraception during study treatment and for at least 7 months after the last dose.

    Inclusion criterion 8

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07454187, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age ≥ 18 years and ≤ 80 years.
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2.
  • Life expectancy ≥ 3 months.
  • Documented diagnosis of multiple myeloma.
  • Measurable disease at screening (per IMWG criteria).
  • Relevant laboratory values obtained within 7 days prior to the first dose must meet protocol-specified thresholds.
  • Resolution of adverse events related to prior antineoplastic therapy to Grade ≤ 1 or baseline (CTCAE v6.0).
  • Female participants of childbearing potential and male participants whose partners are of childbearing potential must use at least one acceptable method of contraception during study treatment and for at least 7 months after the last dose.
  • Male participants must refrain from sperm donation from the signing of the Informed Consent Form (ICF) until at least 7 months after the last study dose.

Exclusion Criteria:

  • Patients with primary refractory multiple myeloma.
  • Presence of non-bone-related extramedullary soft tissue plasmacytoma at screening.
  • known meningeal or Central Nervous System involvement of multiple myeloma, or high suspicion of unconfirmed meningeal or Central Nervous System involvement.
  • History of peripheral neuropathy of Grade ≥ 2.
  • Active infection requiring systemic therapy within 2 weeks prior to the first dose.
  • Hypertension that was not effectively controlled by standardized antihypertensive treatment within 2 weeks prior to the first dose, as judged by the investigator
  • History of hypertensive crisis or hypertensive encephalopathy.
  • Poorly controlled diabetes mellitus.
  • Severe cardiovascular or cerebrovascular disease within 6 months prior to the first dose.
  • Active hepatitis B or hepatitis C infection.
  • Known history of active tuberculosis or active syphilis.
  • Known hypersensitivity to any component of the investigational product.
  • history of Grade 3-4 allergic reaction or life threatening hypersensitivity to any biological product.
  • Received any of the following therapies or surgeries.
  • Prior treatment with LILRB4 targeted therapy; or severe adverse reaction to prior MMAE containing therapy.
  • Immunotherapy, macromolecular targeted therapy, or other antineoplastic biologic therapy within 28 days prior to the first dose.
  • Cytotoxic chemotherapy or small molecule therapy within 14 days prior to the first dose.
  • Modernized traditional Chinese herbal medicine with approved antineoplastic indications within 7 days prior to the first dose.
  • Requirement for systemic corticosteroids (equivalent to > 10 mg prednisone per day) or other immunosuppressive agents within 14 days prior to the first dose or during the study.
  • Administration of any live or live attenuated vaccine within 28 days prior to the first dose.
  • Administration of other vaccines (e.g., inactivated COVID-19 vaccine) within 14 days prior to the first dose.
  • Immune related toxicity during prior antineoplastic immunotherapy that resulted in permanent treatment discontinuation.
  • Current or previous idiopathic pulmonary fibrosis or idiopathic pneumonia;
  • Current acute pulmonary disease, interstitial lung disease, or pneumonia.
  • Any other malignancy diagnosed within 5 years prior to the first dose.
  • Documented history of neurological or psychiatric disorder.
  • Any other condition that, in the opinion of the investigator, may render the participant unsuitable for study participation.

Quoted from ClinicalTrials.gov, NCT07454187, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07454187, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07454187